Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients
NCT02572596
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
rhTPO
DRUG:
CTX
DRUG:
-CSF
Sponsor
Wang Guorong